Chang Junbiao,1born in June, 965, is from Henan. I graduated from the Chemistry Department of Henan University with a bachelor's degree and graduated from the University of Science and Technology of China with a master's degree. After graduation, Chang Junbiao worked in the Institute of Chemistry of Henan Academy of Sciences. In the institute, he served as deputy director and director successively. In 2003, Chang Junbiao ushered in a turning point in his life and became the vice president of Xinxiang Medical College. Since then, I have become attached to colleges and universities in Henan. Professor Chang Junbiao became the vice president of Zhengzhou University in 2006 because of his excellent management ability.
As a well-known scholar in this field, Professor Chang Junbiao has made outstanding achievements in scientific research and become a highly competitive academician candidate. Because of his excellent management ability, he was entrusted with a heavy responsibility as the president of Henan Normal University. Today, he has been in charge of Henan Normal University for many years and has led the school to achieve good results. Therefore, it is a very correct choice for Professor Chang Junbiao to be the principal.
Chang Junbiao's scientific research achievements:
Focusing on the scientific problems and cutting-edge technologies in drug innovation, Chang Junbiao put forward a new concept of antiviral drug design, which makes use of the characteristics of microenvironment RNA polymerase in the process of virus replication to make drugs specifically "in situ" activate and play a role in target cells, and develops a new strategy for nucleoside drug design. It solves the problem that 3' deoxynucleosides can block virus replication, but they are easily recognized by viruses and produce drug resistance. Through structural design, the stability of nucleoside molecules is improved and the half-life is increased.
Official website, School of Chemistry and Chemical Engineering, Henan Normal University, showed that the anti-AIDS drugs 1. 1 developed by Chang Junbiao completed the first and second phase clinical trials from June 5438 to October 2023. 1. 1 A new drug, afudin, can be used for anti-novel coronavirus, and has been approved by the State Administration of Pharmaceutical Products for Phase III clinical treatment of novel coronavirus. BZP( 1. 1), a new drug for treating cerebral infarction, entered the phase II clinical trial. 1. 1 has entered the phase I-II clinical trial.